X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021

Content Team by Content Team
17th December 2020
in News
Gavi, the Vaccine Alliance, Collaborates with Salesforce to Help Equitably Distribute Two Billion COVID-19 Vaccines by the End of 2021

Salesforce, the global leader in CRM, and Gavi, the Vaccine Alliance, announced that they will collaborate to help Gavi manage critical information to equitably distribute approximately two billion COVID-19 vaccines to 190 countries by the end of 2021.

Fair, rapid and equitable access to vaccines is critical to ending the global pandemic. Public-private partnerships, such as Gavi, which are focused on getting vaccines to some of the world’s poorest countries, need to be armed with data and technology to facilitate distribution at scale. The ability to manage huge volumes of country data is essential.

In June, Gavi and other partners launched COVAX, a global alliance whose goal is to ensure that people in all corners of the world get access to COVID-19 vaccines, regardless of their wealth. COVAX will achieve this by supporting the research, development and manufacturing of a wide range of COVID-19 vaccine candidates, and also negotiating pricing and distribution for the 190 countries that have joined the alliance to date.

Gavi needs a single source of truth to help them understand how many vaccines are needed and where. Salesforce Work.com for Vaccines, Experience Cloud and Nonprofit Cloud will power Gavi’s COVAX country engagement platform, which will help them manage critical information. Salesforce is enabling COVAX to move quickly to support fast access to vaccines with a single, secure portal that all participating countries can use to communicate and share information, such as vaccine requirements and access reports. Lower-income countries that are eligible for support by COVAX, will use the portal to provide information to facilitate planning of doses to be rolled out. Higher-income, self-financing countries participating in COVAX will use the portal to get updates about their financial position as that changes over time.

“The scale and urgency of the COVAX mission calls for tools we can expand quickly and use to manage what has become one of the largest and most complex undertakings ever in global health,” said Dr. Seth Berkley, CEO of Gavi. “With our colleagues at Salesforce, we will establish the backbone that allows COVAX participants and partners to share essential information and communicate with greater efficiency and accountability. The partnership will give people worldwide, especially in the poorest countries, access to vaccines that help protect them from COVID-19 and stem the continuing catastrophic social and economic disruption the pandemic has already left in its wake.”

“We’re thrilled to continue our work with Gavi as they embark on one of the largest and most rapid vaccine distribution campaigns of our lifetime,” said Rob Acker, CEO at Salesforce.org. “Leveraging innovative technologies has always been a shared vision of Salesforce.org and Gavi. Now, we are arming 190 countries and economies with the platform they need to communicate critical information around COVID-19 vaccine requirements and equitable distribution for as many as two billion vaccines by the end of 2021.”

 

Previous Post

Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

Next Post

There Is A Lot In Store For Big Pharma

Related Posts

SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Stringent Policy around COVID Vaccines Laid by FDA
FDA Approvals

Stringent Policy around COVID Vaccines Laid by FDA

29th May 2025
Drugmakers Asked to Strictly Follow the US Pricing Reforms
Manufacturing

Drugmakers Asked to Strictly Follow the US Pricing Reforms

28th May 2025
DHL Supply Chain
News

DHL Supply Chain comes up with New Pharma Hub in Singapore

19th April 2025
Healthcare Packaging
Asia

Amcor Healthcare Packaging Expansion in Asia Pacific

16th April 2025
Drug Development

Advanced Instruments All Set To Merge With Nova Biomedical

22nd March 2025
Next Post
The Falling Graph of Dose Contract Manufacturing

There Is A Lot In Store For Big Pharma

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In